Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry

Samantha Jaglowski, MD, Zhen-Huan Hu, MPH, Yiyun Zhang, PhD, Manali Kamdar, MD, Monalisa Ghosh, Premal Lulla, MBBS, Joshua Sasine, MD PhD, Miguel-Angel Perales, MD, Peiman Hematti, MD, Sarah Nikiforow, MD PhD, Patricia Steinert, PhD, Margit Jeschke, PhD, Lan Yi, PhD, Raghav Chawla, MD PhD, Lida Pacaud, Mary M. Horowitz, Eric Bleickardt, MD, Marcelo C. Pasquini, MDMS

Blood (2019) 134 (Supplement_1): 766.

https://doi.org/10.1182/blood-2019-130983

Published: 2019

Journal Articles

Incidence and Risk Factors of De Novo Skin Cancer in a Contemporary Cohort of Hematopoietic Cell Transplantation Survivors

Jennifer Berano Teh, Farah Abdulla, MD, Kelly Peng, Liezl Atencio, Alicia Gonzales, Meagan Echevarria, Alex Iukuridze, Alan Geller, Heeyoung Kim, Lennie Wong, PhD, Stephen J Forman, MD, Ryotaro Nakamura, MD, Badri Modi, MD, Saro H. Armenian, DO, MPH

Blood (2019) 134 (Supplement_1): 2011.

https://doi.org/10.1182/blood-2019-124993

Published: 2019

Journal Articles

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Maria R Vazquez, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Susan O'Brien, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Guillermo Garcia-Manero, MD, Sara E Dellasala, BS, Kathleen A Kehr, MD, Sherry A. Pierce, BSN, BA, Mary B. Rios, RN, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 2927.

https://doi.org/10.1182/blood-2019-132246

Published: 2019

Journal Articles

NUDT15 Variants Confer High Incidence of Secondary Malignancies of ALL in Children

Blood (2019) 134 (Supplement_1): 2751.

https://doi.org/10.1182/blood-2019-125713

Published: 2019

Journal Articles

Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study

Jean-Jacques Kiladjian, MD PhD, Christoph Klade, PhD, Pencho Georgiev, MD, Dorota Krochmalczyk, MD, Liana Gercheva-Kyuchukova, MD, Miklos Egyed, Viktor Rossiev, MD, Petr Dulicek, MD, Árpád Illés, MD D.Sc, Halyna Pylypenko, MD, Lylia Sivcheva, MD, Jiri Mayer, MD, Vera Yablokova, MD, Kurt Krejcy, MD, Hans Hasselbalch, MD, Robert Kralovics, PhD, Heinz Gisslinger, MD

Blood (2019) 134 (Supplement_1): 553.

https://doi.org/10.1182/blood-2019-122233

Published: 2019

Journal Articles

Changing Trends in the Risk Factors of Secondary Primary Malignancies after Autologous Stem Cell Transplantation for Multiple Myeloma before and after the Introduction of Proteasome Inhibitors/Immunomodulatory Agents

Hiroyuki Takamatsu, MD PhD, Shohei Mizuno, MD PhD, Tsutomu Takahashi, MD PhD, Shin-Ichi Fuchida, MD PhD, Ichiro Hanamura, MD PhD, Fumihiko Nakamura, MD PhD, Takehiko Mori, MD PhD, Yuta Katayama, MD PhD, Noriko Doki, MD PhD, Nobuhiro Tsukada, MD PhD, Tatsuo Ichinohe, Yoshinobu Kanda, MD PhD, Yoshiko Atsuta, MD PhD, Kazutaka Sunami, MD PhD

Blood (2019) 134 (Supplement_1): 4358.

https://doi.org/10.1182/blood-2019-123607

Published: 2019

Journal Articles

Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl

Jae H. Park, MD, Jeong-Ok Lee, MD, Richard M. Stone, MD, Alan Saven, MD, Jessica K. Altman, MD, Michael R. Grever, MD, Kanti R Rai, MD, Shreya Vemuri, Omar I Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2018) 132 (Supplement 1): 392.

https://doi.org/10.1182/blood-2018-99-119949

Published: 2018

Journal Articles

Induction with Bortezomib Melphalan and Prednisolon (VMP) Is Associated with Unexpectedly High Discontinuation Rate in Elderly Multiple Myeloma Patients: First Analysis of the German Maintenance (GERMAIN) Trial

Annamaria Brioli, MD, Kirsi Manz, Mathias Hänel, MD, Markus Pfirrmann, PhD, Andreas Christoph Schwarzer, MD, Marie von Lilienfeld-Toal, MD, Gabriele Prange-Krex, Christian Fabisch, PhD, Stefan Knop, Thomas Illmer, MD, Beate Krammer-Steiner, Andreas Hochhaus, MD, Lars-Olof Mügge, MD

Blood (2018) 132 (Supplement 1): 2016.

https://doi.org/10.1182/blood-2018-99-115964

Published: 2018

Journal Articles

Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach

Deborah M. Stephens, Hongli Li, MS, Heiko Schoder, MD, David J. Straus, MD, Craig H. Moskowitz, MD, Michael L. Leblanc, PhD, Lisa M. Rimsza, MD, Nancy L. Bartlett, MD, Andrew M. Evens, DO, MSc, Ann S. LaCasce, MD MSc, Paul Barr, MD, Michael V. Knopp, Eric D. Hsi, MD, John P. Leonard, MD, Brad S Kahl, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2018) 132 (Supplement 1): 929.

https://doi.org/10.1182/blood-2018-99-113034

Published: 2018

Journal Articles

Chronic Lymphocytic Leukemia with Deletion 13q: Prognostic Predictors and Outcome after Treatment with Fludarabine, Cyclophosphamide and Rituximab (FCR)

Abdul Rashid Shah, MD, Tariq Muzzafar, MBBS, Romana Asad, MD, Christine B Peterson, Hagop M. Kantarjian, MD, Alessandra Ferrajoli, MD, William G Wierda, MD PhD, Jan A. Burger, MD PhD, Nitin Jain, MD, Gautam Borthakur, MD, Maliha Khan, MD, Abhishek Chilkulwar, MD, Brion Randolph, MD, Lohith Gowda, MD, Michael J Keating

Blood (2017) 130 (Supplement 1): 5337.

https://doi.org/10.1182/blood.V130.Suppl_1.5337.5337

Published: 2017

Journal Articles

Favorable Immune Signature in CLL Patients, Defined By Antigen-Specific T-Cell Responses, Might Prevent Second Skin Cancers

Annika Nelde, Daniel Johannes Kowalewski, Linus Backert, Lothar Kanz, Helmut R. Salih, MD, Hans-Georg Rammensee, Stefan Stevanovic, Juliane Sarah Walz

Blood (2017) 130 (Supplement 1): 5329.

https://doi.org/10.1182/blood.V130.Suppl_1.5329.5329

Published: 2017

Journal Articles

Transcriptomic and Network Signatures of Cryptic Fusion CBFA2T3-GLIS2 in Pediatric AML Reveals Clinical Considerations and Implications

Jenny L. Smith, MSc, MD, Rhonda E. Ries, MA, Heather Louise Schuback, MD, Lisa E. Brodersen, PhD, Michael R. Loken, PhD, Hamid Bolouri, PhD, Soheil Meshinchi, MD PhD

Blood (2017) 130 (Supplement 1): 1193.

https://doi.org/10.1182/blood.V130.Suppl_1.1193.1193

Published: 2017

Journal Articles

Safety and Efficacy of Ruxolitinib (rux) in an Open-Label, Multicenter, Expanded Treatment Protocol in Patients (Pts) with Polycythemia Vera (PV) Who Are Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatments Are Available

Timothy Devos, MD, Gian Matteo Pica, MD, Hacene Zerazhi, Jan Van Droogenbroeck, Sorin Visanica, Enrique Báez de la Fuente, Brian Leber, MD, Antonio Medina de Almeida, MD PhD, Dana Ranta, Tomasa Martinez, Jean-Jacques Kiladjian, MD PhD, Linda Chrit, Zhaoyu Yin, Julian Perez Ronco, Lynda Foltz

Blood (2017) 130 (Supplement 1): 2918.

https://doi.org/10.1182/blood.V130.Suppl_1.2918.2918

Published: 2017

Journal Articles

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study

Jia Ruan, MD PhD, Peter Martin, FRCPC, MD MS, Paul J Christos, Dr.P.H., M.S., Leandro Cerchietti, MD, Bijal D. Shah, MD, Stephen J. Schuster, MD, Wayne Tam, MD PhD, Amelyn Rodriguez, BSN, RN, OCN, David Hyman, Maria Nieves Calvo Vidal, PhD, Lidia Roman Gonzalez, Sonali M. Smith, MD, Jakub Svoboda, MD, Richard R. Furman, MD, Morton Coleman, MD, John P. Leonard, MD

Blood (2017) 130 (Supplement 1): 154.

https://doi.org/10.1182/blood.V130.Suppl_1.154.154

Published: 2017

Journal Articles

Common Genetic Polymorphisms Contribute to the Association between Non-Melanoma Skin Cancer and Chronic Lymphocytic Leukemia

Caroline Besson, MDPhD, Amy Moore, Wenting Wu, Nicola J Camp, PhD, Claire Vajdic, Lindsay M. Morton, PhD, Karin E Smedby, MD PhD, Silvia de Sanjose, Tait D Shanafelt, MD, Jerry Brewer, Lydia Zablotska, Eric A. Engels, MD MPH, James R. Cerhan, MD PhD, Susan L Slager, PhD, Jiali Han, Sonja I Berndt, PhD

Blood (2017) 130 (Supplement 1): 1454.

https://doi.org/10.1182/blood.V130.Suppl_1.1454.1454

Published: 2017

Journal Articles

Hydroxyurea Mucocutaneous Toxicity: A Prospective Cohort Study of 110 ET and PV Patients from a Single Institution

Carlos Besses Raebel, MD PhD

Blood (2017) 130 (Supplement 1): 4208.

https://doi.org/10.1182/blood.V130.Suppl_1.4208.4208

Published: 2017

Journal Articles

Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Steven Coutre, MD, John C. Byrd, MD, Peter Hillmen, Jacqueline C. Barrientos, MD, Paul M. Barr, Stephen Devereux, PhD FRCP, FRCPath, Tadeusz Robak, MD PhD, Thomas J. Kipps, MD, PhD, Anna Schuh, MDPhD, Carol Moreno, MD, Richard R. Furman, Jan Burger, MD PhD, Michael O'Dwyer, MD, Paolo Ghia, Rudolph Valentino, PharmD, Samuel Suzuki, MS, MBA, Joi Ninomoto, PharmD, Danelle F. James, MD MAS, Susan M. O'Brien, MD

Blood (2016) 128 (22): 4383.

https://doi.org/10.1182/blood.V128.22.4383.4383

Published: 2016

Journal Articles

Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 Study

Nathan Fowler, MD, Loretta Nastoupil, MD, Sven de Vos, MD PhD, Mark Knapp, MD, Ian W. Flinn, MD PhD, Robert W Chen, MD, Ranjana H Advani, MD, Sumeet Bhatia, MD, Peter Martin, MD, Raul Mena, MD, Samuel Suzuki, MS, MBA, Darrin M. Beaupre, MD PhD, Jutta K. Neuenburg, MD PhD, M. Lia Palomba, MD

Blood (2016) 128 (22): 1804.

https://doi.org/10.1182/blood.V128.22.1804.1804

Published: 2016

Journal Articles

European Post-Approval Safety Study (Registry) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety of Patients Treated with Pomalidomide

Francesco Di Raimondo, Charalampia Kyriakou, Martin Schmidt-Hieber, Marie-Christiane Vekemans, Ángel Ramírez Payer, Pal Tore Bentsen, Birgitta Lauri, Elisabeth Kueenburg, Frederik Lersch, Barbara Rosettani, Pamela Bacon, Torben Plesner, Professor

Blood (2016) 128 (22): 5680.

https://doi.org/10.1182/blood.V128.22.5680.5680

Published: 2016

Journal Articles

Spectrum of Concomitant and Subsequently Diagnosed Second Malignancies in Patients with Chronic Myelomonocytic Leukemia

Daniela Barraco, MD, Terra L. Lasho, PhD, Christy Finke, BS, Aref Al-Kali, MD, Michelle Elliott, MD, Mark R. Litzow, MD, Naseema Gangat, MBBS, Curtis A. Hanson, MD, Ayalew Tefferi, MD, Mrinal M Patnaik, MBBS

Blood (2016) 128 (22): 1989.

https://doi.org/10.1182/blood.V128.22.1989.1989

Published: 2016

NARROW

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry

Incidence and Risk Factors of De Novo Skin Cancer in a Contemporary Cohort of Hematopoietic Cell Transplantation Survivors

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

NUDT15 Variants Confer High Incidence of Secondary Malignancies of ALL in Children

Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study

Changing Trends in the Risk Factors of Secondary Primary Malignancies after Autologous Stem Cell Transplantation for Multiple Myeloma before and after the Introduction of Proteasome Inhibitors/Immunomodulatory Agents

Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl

Induction with Bortezomib Melphalan and Prednisolon (VMP) Is Associated with Unexpectedly High Discontinuation Rate in Elderly Multiple Myeloma Patients: First Analysis of the German Maintenance (GERMAIN) Trial

Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach

Chronic Lymphocytic Leukemia with Deletion 13q: Prognostic Predictors and Outcome after Treatment with Fludarabine, Cyclophosphamide and Rituximab (FCR)

Favorable Immune Signature in CLL Patients, Defined By Antigen-Specific T-Cell Responses, Might Prevent Second Skin Cancers

Transcriptomic and Network Signatures of Cryptic Fusion CBFA2T3-GLIS2 in Pediatric AML Reveals Clinical Considerations and Implications

Safety and Efficacy of Ruxolitinib (rux) in an Open-Label, Multicenter, Expanded Treatment Protocol in Patients (Pts) with Polycythemia Vera (PV) Who Are Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatments Are Available

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study

Common Genetic Polymorphisms Contribute to the Association between Non-Melanoma Skin Cancer and Chronic Lymphocytic Leukemia

Hydroxyurea Mucocutaneous Toxicity: A Prospective Cohort Study of 110 ET and PV Patients from a Single Institution

Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 Study

European Post-Approval Safety Study (Registry) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety of Patients Treated with Pomalidomide

Spectrum of Concomitant and Subsequently Diagnosed Second Malignancies in Patients with Chronic Myelomonocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only